News

Cancer Research9d
Depletion of effector regulatory T cells associates with major response to induction dual immune checkpoint blockade
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Cancer Research5d
Abstract CT185: Trispecific EGFR x cMET x VEGF antibody, TAVO412, has clinical responses in esophageal and lung cancers
Search for other works by this author on: ...
Cancer Research5d
Abstract SY27-02: Exploring the significance of somatic mtDNA mutations in the context of acute leukemia
St. Jude Children's Research Hospital, Memphis, TN.
Cancer Research9d
Abstract 1530: Elucidating the role of exogenous lipids in ferroptosis in castration resistant prostate cancer
Search for other works by this author on: ...
Cancer Research9d
Abstract 410: The BTK degrader BGB-16673 shows anti-tumor activity in marginal zone lymphoma models
IOR - Institute of Oncology Research, Bellinzona, Switzerland.
Cancer Research7d
Former NCI Director to Lead Ohio Cancer Center
W. Kimryn Rathmell, MD, PhD, has accepted the role as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. She was ...
Cancer Research9d
Abstract 4336: Translational PK/PD modeling of MEK inhibitors: Trametinib, cobimetinib and binimetinib
Seda Pharmaceutical Development Services, Stockport, United Kingdom.
Cancer Research9d
Abstract 1591: Mechanisms of BPM31510-induced cell death in cancer: lipid peroxidation and apoptosis pathways
Search for other works by this author on: ...
Cancer Research8d
No NIH Grants for Universities with DEI Programs, Israel Boycotts
The NIH will not award research grants to universities with diversity, equity, and inclusion (DEI) programs or boycotts of Israel, including those against Israeli companies or those that do business ...
Cancer Research9d
Abstract 6331: Prevention of lung cancer growth by an edible mushroom-derived p-terphenyl antioxidant, Vialinin-A
Noorda College of Osteopathic Medicine, LLC, Provo, UT.
Cancer Research9d
Abstract 3503: ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin-expressing cancers
Zymeworks Inc., Vancouver, British Columbia, Canada.
Cancer Research9d
Abstract 1733: XL495 is a potent, selective, and orally bioavailable inhibitor of PKMYT1
Cancer Res (2025) 85 (8_Supplement_1): 1733. Protein kinase, membrane-associated tyrosine/threonine-1 (PKMYT1) phosphorylates cyclin-dependent kinase 1 (CDK1) at threonine-14 (Thr14), inhibiting the ...